11 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94.
Sloan-Kettering Institute For Cancer Research
Identification of novel HSP90a/ß isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating CNS disorders such as Huntington's disease.
Vertex Pharmaceuticals
Correlation between chemotype-dependent binding conformations of HSP90a/ß and isoform selectivity-Implications for the structure-based design of HSP90a/ß selective inhibitors for treating neurodegenerative diseases.
Vertex Pharmaceuticals
Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.
Memorial Sloan-Kettering Cancer Center
Discovery of 2-((4-resorcinolyl)-5-aryl-1,2,3-triazol-1-yl)acetates as potent Hsp90 inhibitors with selectivity over TRAP1.
Daegu-Gyeongbuk Medical Innovation Foundation (Dgmif)
Dual Binding to Orthosteric and Allosteric Sites Enhances the Anticancer Activity of a TRAP1-Targeting Drug.
Ulsan National Institutes Of Science And Technology (Unist)
Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions.
China Pharmaceutical University
New TRAP1 and Hsp90 chaperone inhibitors with cationic components: Preliminary studies on mitochondrial targeting.
University Of Ferrara